Kigawa J - Search Results

1

Irinotecan (CPT-11) combined with cisplatin in patients with refractory or recurrent ovarian cancer.

Sugiyama T, Yakushiji M, Nishida T, Ushijima K, Okura N, Kigawa J, Terakawa N. Sugiyama T, et al. Among authors: kigawa j. Cancer Lett. 1998 Jun 19;128(2):211-8. doi: 10.1016/s0304-3835(98)00065-2. Cancer Lett. 1998. PMID: 9683285 Clinical Trial.

2

Synergistic enhancement of cisplatin cytotoxicity by SN-38, an active metabolite of CPT-11, for cisplatin-resistant HeLa cells.

Minagawa Y, Kigawa J, Ishihara H, Itamochi H, Terakawa N. Minagawa Y, et al. Among authors: kigawa j. Jpn J Cancer Res. 1994 Sep;85(9):966-71. doi: 10.1111/j.1349-7006.1994.tb02976.x. Jpn J Cancer Res. 1994. PMID: 7961127 Free PMC article.

3

Tumor DNA ploidy and prognosis of patients with serous cystadenocarcinoma of the ovary.

Kigawa J, Minagawa Y, Ishihara H, Kanamori Y, Terakawa N. Kigawa J, et al. Cancer. 1993 Aug 1;72(3):804-8. doi: 10.1002/1097-0142(19930801)72:3<804::aid-cncr2820720328>3.0.co;2-n. Cancer. 1993. PMID: 8334634

4

Glutathione S-transferase-pi expression and glutathione concentration in ovarian carcinoma before and after chemotherapy.

Cheng X, Kigawa J, Minagawa Y, Kanamori Y, Itamochi H, Okada M, Terakawa N. Cheng X, et al. Among authors: kigawa j. Cancer. 1997 Feb 1;79(3):521-7. Cancer. 1997. PMID: 9028363

5

Glutathione concentration may be a useful predictor of response to second-line chemotherapy in patients with ovarian cancer.

Kigawa J, Minagawa Y, Kanamori Y, Itamochi H, Cheng X, Okada M, Oishi T, Terakawa N. Kigawa J, et al. Cancer. 1998 Feb 15;82(4):697-702. doi: 10.1002/(sici)1097-0142(19980215)82:4<697::aid-cncr12>3.0.co;2-t. Cancer. 1998. PMID: 9477102

6

Gamma-glutamyl cysteine synthetase up-regulates glutathione and multidrug resistance-associated protein in patients with chemoresistant epithelial ovarian cancer.

Kigawa J, Minagawa Y, Cheng X, Terakawa N. Kigawa J, et al. Clin Cancer Res. 1998 Jul;4(7):1737-41. Clin Cancer Res. 1998. PMID: 9676849

7

Topoisomerase-I activity and response to second-line chemotherapy consisting of camptothecin-11 and cisplatin in patients with ovarian cancer.

Kigawa J, Takahashi M, Minagawa Y, Oishi T, Sugiyama T, Yakushiji M, Terakawa N. Kigawa J, et al. Int J Cancer. 1999 Oct 22;84(5):521-4. doi: 10.1002/(sici)1097-0215(19991022)84:5<521::aid-ijc13>3.0.co;2-x. Int J Cancer. 1999. PMID: 10502731

8

Adenovirus-mediated transfer of a p53 gene in ovarian cancer.

Kigawa J, Terakawa N. Kigawa J, et al. Adv Exp Med Biol. 2000;465:207-14. doi: 10.1007/0-306-46817-4_19. Adv Exp Med Biol. 2000. PMID: 10810628 Review.

9

Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy.

Sugiyama T, Kamura T, Kigawa J, Terakawa N, Kikuchi Y, Kita T, Suzuki M, Sato I, Taguchi K. Sugiyama T, et al. Among authors: kigawa j. Cancer. 2000 Jun 1;88(11):2584-9. Cancer. 2000. PMID: 10861437

10

The role of topoisomerase I inhibitor in cisplatin-resistant ovarian cancer.

Minagawa Y, Kigawa J, Itamochi H, Terakawa N. Minagawa Y, et al. Among authors: kigawa j. Hum Cell. 2001 Sep;14(3):237-43. Hum Cell. 2001. PMID: 11774743 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

189 results

Search Page

Filters